Mammography Screening Market Outlook 2022: United States Opportunity and Demand Analysis, Market Forecast 2017 - 2022
United States mammography screening market is expected to reach more than US$ 5.4 Billion by 2022. Market growth can be attributed to factors such as increasing incidence of breast cancer, increasing awareness related to early breast cancer detection, growing government investments and funding for breast cancer screening, technological advancement in mammography technologies and implementation of several initiatives to create awareness about the early detection of breast cancer.
“Mammography Screening Market Outlook 2022: United States Opportunity and Demand Analysis, Market Forecast 2017-2022” provides a deep and thorough evaluation of the United States mammography screening market. The report provides an in–depth analysis of the breast cancer invasive, in situ and men cases and added breast cancer death figures of both men and women in United States. Furthermore, the report also covered mammography screening population from 2010 to 2022.
Market outlook in value terms has been analyzed based on historical, current and potential trends and the market is projected from 2017 to 2022. Additionally, the report includes assessment of breast cancer clinical trials and mammography reimbursement pattern. The report also explores detailed description of growth drivers and inhibitors of the United States mammography screening market.
The report concludes with the profiles of major manufacturers of mammography system such as Hologic, Siemen Healthineers, Philips Healthcare, Toshiba Medical Systems Corporation and GE Healthcare. The major manufacturers are evaluated on parameters such as business overview and mammography marketed products.
Key Topics Covered in the Report
“Mammography Screening Market Outlook 2022: United States Opportunity and Demand Analysis, Market Forecast 2017-2022” provides a deep and thorough evaluation of the United States mammography screening market. The report provides an in–depth analysis of the breast cancer invasive, in situ and men cases and added breast cancer death figures of both men and women in United States. Furthermore, the report also covered mammography screening population from 2010 to 2022.
Market outlook in value terms has been analyzed based on historical, current and potential trends and the market is projected from 2017 to 2022. Additionally, the report includes assessment of breast cancer clinical trials and mammography reimbursement pattern. The report also explores detailed description of growth drivers and inhibitors of the United States mammography screening market.
The report concludes with the profiles of major manufacturers of mammography system such as Hologic, Siemen Healthineers, Philips Healthcare, Toshiba Medical Systems Corporation and GE Healthcare. The major manufacturers are evaluated on parameters such as business overview and mammography marketed products.
Key Topics Covered in the Report
- United States Breast Cancer Cases (2010 - 2022)
- United States Breast Cancer Mammography Screening Population (2010 – 2022)
- United States Breast Cancer Death (2010 – 2017)
- Market Overview: United States Mammography Screening (2010 – 2022)
- Reimbursement Policies of the United States Breast Cancer Screening
- Breast Cancer Screening Clinical Trail Insight by Phase, Company & Country
- Key Drivers and Inhibitors of the United States Mammography Screening Market
- Key Manufacturers Analysis
- Hologic
- Siemen Healthineers
- Philips Healthcare
- GE Healthcare
- Toshiba Medical Systems Corporation
1. EXECUTIVE SUMMARY
2. BREAST CANCER FACTS
3. UNITED STATES BREAST CANCER CASES & POPULATION (2010 – 2022)
3.1 Breast Cancer Mammography Screening Population (2010 – 2022)
3.2 Breast Cancer Occurrence (2010 – 2022)
3.2.1 Total Breast Cancer Cases
3.2.1.1 Breast Cancer Invasive Cases
3.2.1.2 Breast Cancer In Situ Cases
3.2.1.3 Breast Cancer Men Cases
3.3 Breast Cancer Death (2010 – 2017)
3.3.1 Total Breast Cancer Death
3.3.1.1 Women Breast Cancer Death
3.3.1.2 Men Breast Cancer Death
4. MARKET OVERVIEW: UNITED STATES MAMMOGRAPHY SCREENING (2010 – 2022)
5. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES MAMMOGRAPHY SCREENING MARKET
5.1 Market Drivers
5.2 Market Inhibitors
6. REIMBURSEMENT POLICIES OF THE UNITED STATES MAMMOGRAPHY SCREENING
7. BREAST CANCER SCREENING CLINICAL TRAIL INSIGHT BY PHASE, COMPANY & COUNTRY
7.1 Year 2017
7.2 Year 2016
7.3 Year 2015
8. KEY MANUFACTURERS ANALYSIS
8.1 Hologic
8.1.1 Business Overview
8.1.2 Mammography – Marketed Products
8.2 Siemens Healthineers
8.2.1 Business Overview
8.2.2 Mammography – Marketed Products
8.3 Philips Healthcare
8.3.1 Business Overview
8.3.2 Mammography – Marketed Products
8.4 Toshiba Medical Systems Corporation
8.4.1 Business Overview
8.4.2 Mammography – Marketed Products
8.5 GE Healthcare
8.5.1 Business Overview
8.5.2 Mammography – Marketed Products
2. BREAST CANCER FACTS
3. UNITED STATES BREAST CANCER CASES & POPULATION (2010 – 2022)
3.1 Breast Cancer Mammography Screening Population (2010 – 2022)
3.2 Breast Cancer Occurrence (2010 – 2022)
3.2.1 Total Breast Cancer Cases
3.2.1.1 Breast Cancer Invasive Cases
3.2.1.2 Breast Cancer In Situ Cases
3.2.1.3 Breast Cancer Men Cases
3.3 Breast Cancer Death (2010 – 2017)
3.3.1 Total Breast Cancer Death
3.3.1.1 Women Breast Cancer Death
3.3.1.2 Men Breast Cancer Death
4. MARKET OVERVIEW: UNITED STATES MAMMOGRAPHY SCREENING (2010 – 2022)
5. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES MAMMOGRAPHY SCREENING MARKET
5.1 Market Drivers
5.2 Market Inhibitors
6. REIMBURSEMENT POLICIES OF THE UNITED STATES MAMMOGRAPHY SCREENING
7. BREAST CANCER SCREENING CLINICAL TRAIL INSIGHT BY PHASE, COMPANY & COUNTRY
7.1 Year 2017
7.2 Year 2016
7.3 Year 2015
8. KEY MANUFACTURERS ANALYSIS
8.1 Hologic
8.1.1 Business Overview
8.1.2 Mammography – Marketed Products
8.2 Siemens Healthineers
8.2.1 Business Overview
8.2.2 Mammography – Marketed Products
8.3 Philips Healthcare
8.3.1 Business Overview
8.3.2 Mammography – Marketed Products
8.4 Toshiba Medical Systems Corporation
8.4.1 Business Overview
8.4.2 Mammography – Marketed Products
8.5 GE Healthcare
8.5.1 Business Overview
8.5.2 Mammography – Marketed Products
LIST OF FIGURES:
Figure 3–1: United States – Breast Cancer Mammography Screening Population(Thousand),2010 – 2016
Figure 3–2: United States – Breast Cancer Mammography Screening Population(Thousand),2017 – 2022
Figure 3–3: United States – Total Breast Cancer Cases(Number),2010 – 2016
Figure 3–4: United States – Forecast for Total Breast Cancer Cases(Number),2017 – 2022
Figure 3–5: United States – Breast Cancer Invasive Cases(Number),2010 – 2016
Figure 3–6: United States – Forecast for Breast Cancer Invasive Cases(Number),2017 – 2022
Figure 3–7: United States – Breast Cancer In Situ Cases(Number),2010 – 2016
Figure 3–8: United States – Forecast for Breast Cancer In Situ Cases(Number),2017 – 2022
Figure 3–9: United States – Breast Cancer Men Cases(Number),2010 – 2016
Figure 3–10: United States – Forecast for Breast Cancer Men Cases(Number),2017 – 2022
Figure 3–11: United States – Total Breast Cancer Death(Number),2010 – 2017
Figure 3–12: United States – Women Breast Cancer Death(Number),2010 – 2017
Figure 3–13: United States – Men Breast Cancer Death(Number),2010 – 2017
Figure 6–1: United States – Mammography Screening Market (Million US$),2010 – 2016
Figure 6–2: United States – Forecast for Mammography Screening Market (Million US$),2017 – 2022
Figure 3–1: United States – Breast Cancer Mammography Screening Population(Thousand),2010 – 2016
Figure 3–2: United States – Breast Cancer Mammography Screening Population(Thousand),2017 – 2022
Figure 3–3: United States – Total Breast Cancer Cases(Number),2010 – 2016
Figure 3–4: United States – Forecast for Total Breast Cancer Cases(Number),2017 – 2022
Figure 3–5: United States – Breast Cancer Invasive Cases(Number),2010 – 2016
Figure 3–6: United States – Forecast for Breast Cancer Invasive Cases(Number),2017 – 2022
Figure 3–7: United States – Breast Cancer In Situ Cases(Number),2010 – 2016
Figure 3–8: United States – Forecast for Breast Cancer In Situ Cases(Number),2017 – 2022
Figure 3–9: United States – Breast Cancer Men Cases(Number),2010 – 2016
Figure 3–10: United States – Forecast for Breast Cancer Men Cases(Number),2017 – 2022
Figure 3–11: United States – Total Breast Cancer Death(Number),2010 – 2017
Figure 3–12: United States – Women Breast Cancer Death(Number),2010 – 2017
Figure 3–13: United States – Men Breast Cancer Death(Number),2010 – 2017
Figure 6–1: United States – Mammography Screening Market (Million US$),2010 – 2016
Figure 6–2: United States – Forecast for Mammography Screening Market (Million US$),2017 – 2022
